Clinical trials: SARS-COV-2 Infection
SARS-CoV-2 Infection
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects
This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects.
- Trial name
- NCT05017168
- Testing
- CT-P63
- Where
- Poland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celltrion
COVID-19
Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting
The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in reducing the rate of of coronavirus disease 2019 (COVID-19) related hospitalization or all-cause death in non-hospitalized participants with…
- Trial name
- NCT04501952
- Testing
- RDV
- Where
- 104 sites in United States, Denmark and 2 more
- Volunteers
- 584 people
- Sponsor
- Gilead Sciences
Covid19
Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19
This study is a phase III clinical trial to evaluate efficacy, reactogenicity and safety of the vaccine Ad5-nCoV compared with placebo in volunteers at the age from 18 to 85 years，with the randomized, double-blind design
- Trial name
- NCT04540419
- Testing
- Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
- Where
- 7 sites in Russia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
COVID-19
Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong
This is a randomized, double-blinded, Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate to evaluate the changes in…
- Trial name
- NCT05254236
- Testing
- COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose), COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19, SARS-CoV-2
Secondary Databased Post-marketing Surveillance Study of BNT162b2
This study is to assess the post-marketing safety of BNT162b2 products using nationwide population-based database in Republic of Korea.
- Trial name
- NCT06743334
- Testing
- Tozinameran (BNT162b2), Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1), Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)
- Where
- South Korea
- Volunteers
- 14,302,529 people
- Sponsor
- Pfizer
COVID-19 Respiratory Infection, COVID-19
Efficacy and Safety Study of Essential Oil-Based Preparation Administered to COVID-19 Patients
The aim of this study was to compare the efficacy and safety of the essential oil-based product in patients with mild to moderate symptomatic COVID-19 Positive infection confirmed by PCR.
- Trial name
- NCT06452069
- Testing
- IMMUNO19
- Where
- 10 sites in Turkey (Türkiye)
- Volunteers
- 280 people
- Sponsor
- Biodex S.A
Covid19
Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients.
This is a phase I/II study with Amorphous Calcium Carbonate (ACC) administered sublingual and in Inhalation concomitantly with BAT (Best Available Care) as Compared to Placebo and BAT for the treatment of Moderate to Severe…
- Trial name
- NCT04900337
- Testing
- AMOR 18 Powder & Inhalation
- Where
- 3 sites in Israel
- Volunteers
- 66 people
- Sponsor
- Amorphical Ltd.
Identify the Viral Epitopes of Memory CD8 T Cells From Individuals That Have Recovered From SARS-CoV-2 Infection, Determine Which SARS-CoV-2 Proteins Are Frequently Recognized by T Cells in Patients With Varying HLA Types
Blood Collection Study From COVID-19 Convalescents Previously Hospitalized to Identify Immunogenic Viral Epitopes
The COVID-19 pandemic is a global emergency threatening to take millions of lives in the United States and around the world. There is no current vaccine strategy against COVID-19 infection caused by a novel coronavirus named…
- Trial name
- NCT04397900
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- TScan Therapeutics, Inc.
Pulmonary Alveolar Proteinosis, COPD
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality.
- Conditions
- Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia
- Trial name
- GARM-COVID19 (NCT04326036)
- Testing
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Black Tie Medical, Inc.
COVID-19
Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19
The purpose of the study is to assess the safety and efficacy of ATR-002 (in addition to standard-of-care) for the treatment of COVID-19
- Trial name
- RESPIRE (NCT04776044)
- Testing
- ATR-002
- Where
- 40 sites in Germany, India and 5 more
- Volunteers
- 133 people
- Sponsor
- Atriva Therapeutics GmbH
Healthy Participants
A Study to Learn About the Study Medicine PF-07321332 and Ritonavir in Adult Healthy Chinese Participants.
The purpose of this Phase 1 clinical trial is to help us understand how the drug is changed and eliminated from your body after you take it, the safety, and the the extent to which dise effects can be tolerated of PF-07321332…
- Trial name
- NCT05339334
- Testing
- PF-07321332/ritonavir
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19.
- Trial name
- BLAZE-4 (NCT04634409)
- Testing
- Bamlanivimab, Etesevimab, VIR-7831
- Where
- 141 sites in United States, Argentina and 1 more
- Volunteers
- 1,755 people
- Sponsor
- Eli Lilly and Company
SARS-CoV2 Infection
Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)
The primary objective of this study is to provide expanded access of remdesivir (RDV) for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.
- Trial name
- NCT04323761
- Testing
- Remdesivir
- Where
- 272 sites in United States, Australia and 25 more
- Sponsor
- Gilead Sciences
SARS-CoV-2, Influenza A
POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.
This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 Ag Ultra test in detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and LumiraDx SARS-CoV-2 \& Flu A/B…
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, COVID-19
- Trial name
- PURSUE (NCT05728970)
- Testing
- LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B
- Where
- 10 sites in United States
- Volunteers
- 716 people, healthy volunteers welcome
- Sponsor
- LumiraDx UK Limited
Covid19, HIV-1-infection
An Open-label Clinical Study of the Pharmacokinetics and Safety of Elsulfavirine, 200 mg Tablets, With Single and Multiple Oral Administration in Healthy Volunteers
An open-label clinical study of the pharmacokinetics and safety of Elsulfavirine, 200 mg tablets, with single and multiple oral administration in healthy volunteers.
- Trial name
- NCT05148754
- Testing
- Elsulfavirine
- Where
- Russia
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Viriom
COVID-19, Infection Viral
A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers
An open label, dose escalation, and dose expansion study to evaluate the safety, reactogenicity and immunogenicity of two SARS-CoV-2 DNA plasmid vaccine candidates, VB10.2129 (C1) and VB10.2210 (C2).
- Conditions
- COVID-19, Infection Viral, Infections
- Trial name
- NCT05069623
- Testing
- VB10.2129, VB10.2210
- Where
- 2 sites in Norway
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Nykode Therapeutics ASA
Biological Availability
Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.
The purpose of this study is to estimate the relative bioavailability (rBA) of nirmatrelvir/ritonavir oral powder in 3 different food vehicles relative to the Paxlovid® tablets under fasted condition in healthy adult…
- Trial name
- NCT05544786
- Testing
- Nirmatrelvir/ ritonavir, Nirmatrelvir/Ritonavir
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19
Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19
This clinical trial is a randomized, blinded, two arms, placebo controlled, clinical trial to evaluate the safety and efficacy of Mycobacterium w in combination with standard care as per hospital practice to prevent COVID 19 in…
- Trial name
- NCT04353518
- Testing
- Suspension of heat killed (autoclaved) Mycobacterium w
- Where
- 3 sites in India
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Cadila Pharnmaceuticals
COVID-19
Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)
The purpose of the study is to determine if high dose Intravenous IVIG plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day 29 or who are dependent on high…
- Trial name
- NCT04432324
- Testing
- Intravenous Immune Globulin, Standard Medical Treatment
- Where
- 10 sites in Spain
- Volunteers
- 100 people
- Sponsor
- Instituto Grifols, S.A.
COVID-19
Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant
2019nCoV-101 is a 2-part, randomized, observer-blinded, placebo-controlled, Phase 1/2 trial. Part 1 (Phase 1) of the study is designed to evaluate the safety and immunogenicity of SARS-CoV-2 rS nanoparticle vaccine with or…
- Trial name
- NCT04368988
- Testing
- SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1
- Where
- 18 sites in United States, Australia
- Volunteers
- 1,419 people, healthy volunteers welcome
- Sponsor
- Novavax
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.